In Alzheimer’s disease (AD), the amyloid β-peptide was shown to induce changes in TJ and AJ proteins including claudin-5, occludin, ZO-1 and VE-cadherin causing dysfunction of the barrier and increased vascular permeability in AD patients [8, 15, 16]. This evidence concerns the gene CLDN5 and Alzheimer disease.